JP2008508859A5 - - Google Patents

Download PDF

Info

Publication number
JP2008508859A5
JP2008508859A5 JP2007513935A JP2007513935A JP2008508859A5 JP 2008508859 A5 JP2008508859 A5 JP 2008508859A5 JP 2007513935 A JP2007513935 A JP 2007513935A JP 2007513935 A JP2007513935 A JP 2007513935A JP 2008508859 A5 JP2008508859 A5 JP 2008508859A5
Authority
JP
Japan
Prior art keywords
binding molecule
seq
pharmaceutical composition
rabies virus
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007513935A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008508859A (ja
JP4768730B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2005/052410 external-priority patent/WO2005118644A2/en
Publication of JP2008508859A publication Critical patent/JP2008508859A/ja
Publication of JP2008508859A5 publication Critical patent/JP2008508859A5/ja
Application granted granted Critical
Publication of JP4768730B2 publication Critical patent/JP4768730B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007513935A 2004-05-27 2005-05-26 狂犬病ウイルスを中和することができる結合分子およびそれらの用途 Expired - Fee Related JP4768730B2 (ja)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US57502304P 2004-05-27 2004-05-27
EP2004050943 2004-05-27
US60/575,023 2004-05-27
EPPCT/EP2004/050943 2004-05-27
EPPCT/EP2004/051661 2004-07-29
EP2004051661 2004-07-29
EP2004052286 2004-09-23
EPPCT/EP2004/052286 2004-09-23
EPPCT/EP2004/052772 2004-11-03
EP2004052772 2004-11-03
EPPCT/EP2005/050310 2005-01-25
EP2005050310 2005-01-25
EPPCT/EP2005/050953 2005-03-03
EP2005050953 2005-03-03
PCT/EP2005/052410 WO2005118644A2 (en) 2004-05-27 2005-05-26 Binding molecules capable of neutralizing rabies virus and uses thereof

Publications (3)

Publication Number Publication Date
JP2008508859A JP2008508859A (ja) 2008-03-27
JP2008508859A5 true JP2008508859A5 (enExample) 2008-07-10
JP4768730B2 JP4768730B2 (ja) 2011-09-07

Family

ID=34968690

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007513935A Expired - Fee Related JP4768730B2 (ja) 2004-05-27 2005-05-26 狂犬病ウイルスを中和することができる結合分子およびそれらの用途

Country Status (22)

Country Link
US (5) US7579446B2 (enExample)
EP (3) EP2314621B1 (enExample)
JP (1) JP4768730B2 (enExample)
KR (2) KR101228157B1 (enExample)
CN (5) CN102139106B (enExample)
AT (1) ATE501171T1 (enExample)
AU (1) AU2005250163B2 (enExample)
BR (1) BRPI0511479C1 (enExample)
CA (1) CA2568162C (enExample)
CU (1) CU23719A3 (enExample)
CY (1) CY1111550T1 (enExample)
DK (1) DK1749029T3 (enExample)
EA (1) EA010785B1 (enExample)
ES (2) ES2426725T3 (enExample)
HR (3) HRP20110320T1 (enExample)
IL (3) IL179586A (enExample)
MX (1) MXPA06013482A (enExample)
NZ (2) NZ580607A (enExample)
PL (3) PL2314620T3 (enExample)
PT (3) PT1749029E (enExample)
RS (2) RS53269B (enExample)
WO (1) WO2005118644A2 (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7550140B2 (en) * 2002-06-13 2009-06-23 Crucell Holland B.V. Antibody to the human OX40 receptor
AU2003256299A1 (en) 2002-07-01 2004-01-19 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
SI1523496T1 (sl) 2002-07-18 2011-11-30 Merus B V Rekombinantno proizvajanje zmesi protiteles
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
EP2395017A3 (en) 2003-05-30 2012-12-19 Merus B.V. Design and use of paired variable regions of specific binding molecules
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
NZ543635A (en) 2003-06-25 2008-05-30 Crucell Holland Bv Human C-type lectin: a suitable target molecule for binding molecules, particularly immunoconjugates, in the diagnosis, prevention and/or treatment of myeloid neoplastic diseases such as AML and CML
KR101206206B1 (ko) * 2003-07-22 2012-11-29 크루셀 홀란드 비.브이. 사스-코로나바이러스에 대한 결합분자 및 그것의 용도
CN102139106B (zh) 2004-05-27 2014-10-08 克鲁塞尔荷兰公司 能中和狂犬病病毒的结合分子及其应用
JP4852046B2 (ja) * 2004-10-12 2012-01-11 クルセル ホランド ベー ヴェー 癌の治療及び検出に用いる結合分子
WO2006120230A2 (en) 2005-05-12 2006-11-16 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
WO2007031550A2 (en) * 2005-09-15 2007-03-22 Crucell Holland B.V. Method for preparing immunoglobulin libraries
US7807645B2 (en) 2005-09-23 2010-10-05 The Regents Of The University Of California Method of treating degenerative disorders of the nervous system by administration of fibrinogen fragment
EP3018142A1 (en) 2006-06-06 2016-05-11 Crucell Holland B.V. Human binding molecules having killing activity against staphylococci and uses thereof
JP5586952B2 (ja) 2006-06-06 2014-09-10 クルセル ホランド ベー ヴェー 腸球菌に対する殺活性を有するヒトの結合分子及びその使用方法
MY170607A (en) * 2006-09-07 2019-08-20 Crucell Holland Bv Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
MX2009005414A (es) * 2006-12-05 2009-06-01 Crucell Holland Bv Formulaciones liquidas de anticuerpo antirrabico.
CA2689941C (en) 2007-06-25 2019-10-29 Esbatech Ag Methods of modifying antibodies, and modified antibodies with improved functional properties
JO2913B1 (en) * 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
US8877199B2 (en) 2009-05-15 2014-11-04 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services B cell surface reactive antibodies
US8821879B2 (en) 2009-09-04 2014-09-02 Xoma Technology Ltd. Anti-botulism antibody coformulations
GEP20166458B (en) * 2009-10-02 2016-04-11 Ze Rejents Ov Ze Universiti Ov Kalifornia Monoclonal antibodies
CN101696242B (zh) * 2009-10-26 2011-12-28 中国人民解放军南京军区军事医学研究所 人源抗狂犬病毒中和抗体Fab及其制备方法和应用
WO2011080765A2 (en) * 2010-01-04 2011-07-07 Indian Immunologicals Limited Recombinant human bivalent diabody against rabies virus and uses thereof
EP2894221B1 (en) * 2010-02-19 2017-10-11 Japan Science and Technology Agency Human abzyme
DK3345615T3 (da) 2010-03-01 2020-01-20 Bayer Healthcare Llc Optimerede monoklonale antistoffer mod inhibitor af vævsfaktoraktiveringsvejen (tfpi)
CN103003307B (zh) 2010-03-10 2017-08-11 根马布股份公司 抗c‑MEt的单克隆抗体
JP2013538042A (ja) * 2010-06-16 2013-10-10 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション エンドプラスミンに対する抗体およびその使用
KR101388680B1 (ko) * 2011-03-18 2014-04-28 (주)셀트리온 광견병 바이러스를 중화시킬 수 있는 결합 분자
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
KR101495019B1 (ko) 2011-09-30 2015-02-24 (주)셀트리온 광견병 바이러스를 중화시킬 수 있는 결합 분자
CA2870821C (en) 2012-04-20 2022-06-14 Merus B.V. Methods and means for the production of ig-like molecules
CN102924571A (zh) * 2012-10-29 2013-02-13 复旦大学 狂犬病毒糖蛋白与核蛋白的抗原表位多肽及其筛选、鉴定方法与应用
WO2015088256A1 (ko) * 2013-12-12 2015-06-18 (주)셀트리온 광견병 바이러스를 중화시킬 수 있는 결합 분자
CN103954777A (zh) * 2014-05-20 2014-07-30 北京凯思百奥科技发展有限公司 一种狂犬病病毒单克隆抗体及其应用
RU2549971C1 (ru) * 2014-07-01 2015-05-10 Федеральное казённое учреждение здравоохранения Ставропольский научно-исследовательский противочумный институт Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Способ консервации иммунопероксидазного конъюгата
CN104761640A (zh) * 2015-02-03 2015-07-08 中国食品药品检定研究院 具有中和活性的抗狂犬病病毒单克隆抗体的制备及应用
IL292578A (en) * 2015-02-13 2022-06-01 Sorrento Therapeutics Inc Antibody therapeutics that bind ctla4
WO2016200189A1 (ko) * 2015-06-10 2016-12-15 (주)셀트리온 광견병 바이러스 g 단백질의 에피토프 및 이에 특이적으로 결합하는 광견병 바이러스 중화 결합 분자
JP7022067B2 (ja) * 2016-01-14 2022-02-17 メモリアル スローン ケタリング キャンサー センター Ｆｏｘｐ３由来のペプチドに特異的なｔ細胞受容体様抗体
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
RU2718835C2 (ru) * 2017-12-29 2020-04-15 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Нейтрализующее моноклональное антитело, связывающееся с гликопротеином g вируса бешенства, фрагменты днк, кодирующие указанное антитело, и антигенсвязывающий фрагмент
WO2019227039A1 (en) * 2018-05-24 2019-11-28 Lankenau Institute For Medical Research Compositions comprising antibodies to rabies virus and the uses thereof
CN110317267B (zh) * 2018-08-09 2020-11-20 北京智仁美博生物科技有限公司 针对狂犬病病毒的双特异性抗体及其用途
EP3929214A4 (en) * 2019-05-30 2022-06-22 Shandong Boan Biotechnology Co., Ltd. ANTIBODY OR CHIMERIC ANTIGEN RECEPTOR TARGETING CLAUDIN 18.2
CN111171145B (zh) * 2020-01-21 2021-11-05 兰州生物制品研究所有限责任公司 一种抗狂犬病病毒单克隆抗体、制备方法及用途
EP4157868A1 (en) * 2020-05-26 2023-04-05 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
CN117440973A (zh) * 2021-04-09 2024-01-23 索伦托药业有限公司 与ror1结合的抗原结合蛋白
CN114397453B (zh) * 2022-03-25 2022-06-07 江苏美克医学技术有限公司 新型冠状病毒突变株的检测试剂盒及其应用
CN119930826A (zh) * 2023-11-02 2025-05-06 重庆精准生物产业技术研究院有限公司 针对psca的全人源单链抗体及其应用
CN117777282B (zh) * 2023-12-07 2025-03-04 兰州生物制品研究所有限责任公司 一种抗狂犬病病毒中和抗体及其制备和应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
DE69005908T2 (de) * 1989-06-08 1994-04-28 Wistar Inst Philadelphia Monoklonale Antikörper zur Behandlung nach einem Kontakt mit Tollwutvirus.
US6248574B1 (en) 1989-12-13 2001-06-19 Avigdor Shaffermann Polypeptides selectively reactive with antibodies against human immunodeficiency virus and vaccines comprising the polypeptides
DE4006630A1 (de) * 1990-03-03 1991-09-12 Behringwerke Ag Humane monoklonale antikoerper gegen tollwutviren, ihre herstellung und verwendung
NL9101953A (nl) 1991-11-21 1993-06-16 Seed Capital Investments Testinrichting omvattende een plaat met een veelvoud van putjes met een bijbehorende doseerinrichting, alsmede een kit die deze inrichtingen omvat en toepassing van de inrichtingen.
US5624949A (en) 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
CA2267139A1 (en) * 1996-10-08 1998-04-16 Ton Logtenberg Methods and means for selecting peptides and proteins having specific affinity for a target
WO2000063403A2 (en) 1999-04-15 2000-10-26 Crucell Holland B.V. Recombinant protein production in a human cell using sequences encoding adenovirus e1 protein
US7071319B2 (en) * 2000-05-16 2006-07-04 Thomas Jefferson University Recombinant antibodies, and compositions and methods for making and using the same
US20040013672A1 (en) * 2000-05-16 2004-01-22 Thomas Jefferson University Recombinant antibodies, and compositions and methods for making and using the same
DK1402025T3 (da) 2001-06-15 2006-06-06 Crucell Holland Bv Kimære fager
WO2003016501A2 (en) * 2001-08-21 2003-02-27 Thomas Jefferson University Recombinant antibodies, and compositions and methods for making and using the same
US7550140B2 (en) * 2002-06-13 2009-06-23 Crucell Holland B.V. Antibody to the human OX40 receptor
SI1523496T1 (sl) * 2002-07-18 2011-11-30 Merus B V Rekombinantno proizvajanje zmesi protiteles
US20100069614A1 (en) * 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
NZ543635A (en) 2003-06-25 2008-05-30 Crucell Holland Bv Human C-type lectin: a suitable target molecule for binding molecules, particularly immunoconjugates, in the diagnosis, prevention and/or treatment of myeloid neoplastic diseases such as AML and CML
KR101206206B1 (ko) 2003-07-22 2012-11-29 크루셀 홀란드 비.브이. 사스-코로나바이러스에 대한 결합분자 및 그것의 용도
EP1718670B1 (en) 2004-02-27 2011-07-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Il-15 binding site for il 15-ralpha and specific il-15 mutants having agonist/antagonist activity
CN102139106B (zh) * 2004-05-27 2014-10-08 克鲁塞尔荷兰公司 能中和狂犬病病毒的结合分子及其应用
ATE550037T1 (de) 2004-11-11 2012-04-15 Crucell Holland Bv Zusammensetzungen gegen das sars-coronavirus und ihre verwendungen
CA2591665C (en) 2004-12-20 2015-05-05 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
AU2005330672B2 (en) 2005-04-18 2011-07-28 Yeda Research And Development Company Limited Stabilized anti-hepatitis B (HBV) antibody formulations
WO2006120230A2 (en) 2005-05-12 2006-11-16 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
EP1893645A1 (en) 2005-06-23 2008-03-05 Crucell Holland B.V. Optimization of west nile virus antibodies
CN101389611B (zh) * 2006-02-27 2012-07-18 伊兰制药公司 抑制由vla-4所介导的白血球粘附的嘧啶磺酰胺化合物
JP5586952B2 (ja) * 2006-06-06 2014-09-10 クルセル ホランド ベー ヴェー 腸球菌に対する殺活性を有するヒトの結合分子及びその使用方法
EP3018142A1 (en) * 2006-06-06 2016-05-11 Crucell Holland B.V. Human binding molecules having killing activity against staphylococci and uses thereof
MY170607A (en) * 2006-09-07 2019-08-20 Crucell Holland Bv Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
MX2009005414A (es) 2006-12-05 2009-06-01 Crucell Holland Bv Formulaciones liquidas de anticuerpo antirrabico.

Similar Documents

Publication Publication Date Title
JP2008508859A5 (enExample)
JP2010502207A5 (enExample)
WO2008079372A3 (en) Novel immunogenic compositions for the prevention and treatment of meningococcal disease
JP2006526414A5 (enExample)
JP2005511076A5 (enExample)
JP2008529558A5 (enExample)
JP2019511222A5 (enExample)
JP2011250797A5 (enExample)
JP2005503789A5 (enExample)
WO2011020783A3 (en) Targeted immunoconjugates
JP2010516290A5 (enExample)
WO2003063766A3 (en) Novel immunogenic compositions for the prevention and treatment of meningococcal disease
NZ595387A (en) Peptides for treatment and diagnosis of autoimmune disease
RU2007139915A (ru) Haemophilus influenzae типа в
JP2010166916A5 (enExample)
MXPA05011110A (es) Composiciones inmunogenicas novedosas para la prevencion y tratamiento de un padecimiento originado por meningococos.
ATE535252T1 (de) Peptid-konjugat-zusammensetzungen und -verfahren zur prävention und behandlung von alzheimer- krankheit
HRP20110320T1 (hr) Molekule za vezanje koje mogu neutralizirati virus bjesnoće i njihova uporaba
JP2008538183A5 (enExample)
IL187321A (en) Molecules that have a specific link to a surrogate cell that encode monoclonal antibodies capable of neutralizing viruses, medicinal preparations containing them, and their uses in drug preparation
JP2008536483A5 (enExample)
JP2008525033A5 (enExample)
JP2009520758A5 (enExample)
WO2009079481A3 (en) Methods to diagnose and immunize against the virus causing human merkel cell carcinoma
CN1610697A (zh) 戊型肝炎病毒单克隆抗体或其结合活性片段及其用途